Cargando…

The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells

Diabetes is one of the leading chronic diseases globally with a significant impact on mortality. This condition is associated with chronic microvascular and macrovascular complications caused by vascular damage. Recently, endothelial progenitor cells (EPCs) raised interest due to their regenerative...

Descripción completa

Detalles Bibliográficos
Autores principales: Altabas, Velimir, Marinković Radošević, Jelena, Špoljarec, Lucija, Uremović, Stella, Bulum, Tomislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669792/
https://www.ncbi.nlm.nih.gov/pubmed/38002051
http://dx.doi.org/10.3390/biomedicines11113051
_version_ 1785149253530681344
author Altabas, Velimir
Marinković Radošević, Jelena
Špoljarec, Lucija
Uremović, Stella
Bulum, Tomislav
author_facet Altabas, Velimir
Marinković Radošević, Jelena
Špoljarec, Lucija
Uremović, Stella
Bulum, Tomislav
author_sort Altabas, Velimir
collection PubMed
description Diabetes is one of the leading chronic diseases globally with a significant impact on mortality. This condition is associated with chronic microvascular and macrovascular complications caused by vascular damage. Recently, endothelial progenitor cells (EPCs) raised interest due to their regenerative properties. EPCs are mononuclear cells that are derived from different tissues. Circulating EPCs contribute to regenerating the vessel’s intima and restoring vascular function. The ability of EPCs to repair vascular damage depends on their number and functionality. Diabetic patients have a decreased circulating EPC count and impaired EPC function. This may at least partially explain the increased risk of diabetic complications, including the increased cardiovascular risk in these patients. Recent studies have confirmed that many currently available drugs with proven cardiovascular benefits have beneficial effects on EPC count and function. Among these drugs are also medications used to treat different types of diabetes. This manuscript aims to critically review currently available evidence about the ways anti-diabetic treatment affects EPC biology and to provide a broader context considering cardiovascular complications. The therapies that will be discussed include lifestyle adjustments, metformin, sulphonylureas, gut glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor analogs, sodium-glucose transporter 2 inhibitors, and insulin.
format Online
Article
Text
id pubmed-10669792
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106697922023-11-14 The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells Altabas, Velimir Marinković Radošević, Jelena Špoljarec, Lucija Uremović, Stella Bulum, Tomislav Biomedicines Review Diabetes is one of the leading chronic diseases globally with a significant impact on mortality. This condition is associated with chronic microvascular and macrovascular complications caused by vascular damage. Recently, endothelial progenitor cells (EPCs) raised interest due to their regenerative properties. EPCs are mononuclear cells that are derived from different tissues. Circulating EPCs contribute to regenerating the vessel’s intima and restoring vascular function. The ability of EPCs to repair vascular damage depends on their number and functionality. Diabetic patients have a decreased circulating EPC count and impaired EPC function. This may at least partially explain the increased risk of diabetic complications, including the increased cardiovascular risk in these patients. Recent studies have confirmed that many currently available drugs with proven cardiovascular benefits have beneficial effects on EPC count and function. Among these drugs are also medications used to treat different types of diabetes. This manuscript aims to critically review currently available evidence about the ways anti-diabetic treatment affects EPC biology and to provide a broader context considering cardiovascular complications. The therapies that will be discussed include lifestyle adjustments, metformin, sulphonylureas, gut glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor analogs, sodium-glucose transporter 2 inhibitors, and insulin. MDPI 2023-11-14 /pmc/articles/PMC10669792/ /pubmed/38002051 http://dx.doi.org/10.3390/biomedicines11113051 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Altabas, Velimir
Marinković Radošević, Jelena
Špoljarec, Lucija
Uremović, Stella
Bulum, Tomislav
The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells
title The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells
title_full The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells
title_fullStr The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells
title_full_unstemmed The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells
title_short The Impact of Modern Anti-Diabetic Treatment on Endothelial Progenitor Cells
title_sort impact of modern anti-diabetic treatment on endothelial progenitor cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669792/
https://www.ncbi.nlm.nih.gov/pubmed/38002051
http://dx.doi.org/10.3390/biomedicines11113051
work_keys_str_mv AT altabasvelimir theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells
AT marinkovicradosevicjelena theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells
AT spoljareclucija theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells
AT uremovicstella theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells
AT bulumtomislav theimpactofmodernantidiabetictreatmentonendothelialprogenitorcells
AT altabasvelimir impactofmodernantidiabetictreatmentonendothelialprogenitorcells
AT marinkovicradosevicjelena impactofmodernantidiabetictreatmentonendothelialprogenitorcells
AT spoljareclucija impactofmodernantidiabetictreatmentonendothelialprogenitorcells
AT uremovicstella impactofmodernantidiabetictreatmentonendothelialprogenitorcells
AT bulumtomislav impactofmodernantidiabetictreatmentonendothelialprogenitorcells